Edition:
United States

People: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

65.85USD
23 Feb 2017
Change (% chg)

$0.56 (+0.86%)
Prev Close
$65.29
Open
$65.50
Day's High
$66.11
Day's Low
$65.35
Volume
2,180,496
Avg. Vol
3,320,383
52-wk High
$66.11
52-wk Low
$49.64

Schechter, Adam 

Mr. Adam H. Schechter is Executive Vice President, President - Global Human Health of Merck & Co., Inc. He is responsible for the Company’s global pharmaceutical and vaccine business. Since November 2009 — President, Global Human Health, U.S. Market-Integration Leader, Merck & Co., Inc. — commercial responsibility in the United States for the Company’s portfolio of prescription medicines. Leader for the integration efforts for the Merck/Schering-Plough merger across all divisions and functions. Since August 2007 — President, Global Pharmaceuticals, Global Human Health, Merck & Co., Inc. — global responsibilities for the Company’s atherosclerosis/cardiovascular, diabetes/obesity, oncology, specialty/neuroscience, respiratory, bone, arthritis and analgesia franchises as well as commercial responsibility in the United States for the Company’s portfolio of prescription medicines. Since July 2006 — President, U.S. Human Health, Merck & Co., Inc. — commercial responsibility in the United States for the Company’s portfolio of prescription medicines.

Basic Compensation

Total Annual Compensation, USD 2,534,900
Restricted Stock Awards, USD 3,310,050
Long-Term Incentive Plans, USD --
All Other, USD 1,664,180
Fiscal Year Total, USD 7,509,130

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 74,200 1,576,830.00